Aberrantly expressed microRNAs (miRNAs) are involved in breast tumorigenesis. It is still unclear if and how miRNAs-221/222 are implicated in breast cancer and the resistance to estrogen receptor modulator tamoxifen. We investigated the roles and mechanisms of miR-221/222 in breast cancer cells, particularly in modulating response to tamoxifen therapy. MCF-7 and MDA-MB-231 breast cancer cells were transfected with antisense oligonucleotides AS-miR-221 and AS-miR-222 and their expression of miR-221 and miR-222 was assessed. The correlation of miR-221/222 with tissue inhibitor of metalloproteinase-3 (TIMP 3 ) expression was investigated by fluorescence quantitative PCR and western blotting analysis. The therapeutic sensitivity of these cells, transfected and untransfected, to tamoxifen was determined. Transfection of AS-miR-221 and AS-miR-222 dramatically inhibited expression of miR-221 and miR-222, respectively, in both MCF-7 and MDA-MB-231 cells (Po0.05-0.01). Downregulation of miR-221/222 significantly increased the expression of TIMP 3 compared with controls (Po0.05-0.01). The viability of estrogen receptor (ER)-positive MCF-7 cells transfected with AS-miR-221 or/and AS-miR-222 was significantly reduced by tamoxifen (Po0.05-0.01). We have demonstrated for the first time that suppression of miRNA-221/222 increases the sensitivity of ER-positive MCF-7 breast cancer cells to tamoxifen. This effect is mediated through upregulation of TIMP 3 . These findings suggest that upregulation of TIMP 3 via inhibition of miRNA-221/222 could be a promising therapeutic approach for breast cancer.
INTRODUCTION
Despite advances in early diagnosis and therapy, breast cancer is still the leading cause of cancer death in women worldwide. 1 Gene profiling studies have been used extensively over the past decade as a powerful tool to define the signatures of different cancers and to predict their outcome and response to treatment. The estrogen dependence of breast cancer was first recognized more than a century ago when oophorectomy was shown to cause regression of mammary tumors in a subset of premenopausal women. 2 Subsequent studies have consistently demonstrated an increased risk of breast cancer associated with elevated levels of estrogen. 2, 3 Over two-thirds of breast cancers exhibit high concentrations of estrogen receptor (ER) that contributes to tumor growth and is the rationale for ER modulators such as tamoxifen as a therapeutic strategy. Tamoxifen, an important cancer drug, was the first targeted therapy developed against ER-positive breast cancers and is currently the only adjuvant endocrine therapy approved for premenopausal women with this cancer subtype. 4 Unfortunately, B30% of ER-positive breast cancers either fail to respond to tamoxifen or become resistant over time. 5 Micro-RNAs (miRNAs), a class of small (18-24 nucleotides), noncoding RNA molecules, are important regulators of gene expression and biological functions. [6] [7] [8] MiRNAs are involved in temporal and tissue-specific eukaryotic gene regulation, 9 either by translational inhibition or exonucleolytic mRNA decay, targeted through imperfect complementarity between the miRNA and the 3 0 -untranslated region of the mRNA. [10] [11] [12] [13] [14] Because of their ability to potentially target any human mRNA, it is likely that miRNAs are involved in almost every biological process, including cell cycle regulation and cell growth, apoptosis, differentiation and stress response. [15] [16] [17] Altered miRNA expression has been found in breast cancer. 18, 19 Miller et al. 20 explored the potential role of specific miRNAs in inducing tamoxifen resistance in breast cancer and demonstrated that miR-221 and miR-222 are upregulated in tamoxifen-resistant breast cancer cell lines and HER2-positive primary human breast tumors. MiR-221 and its close homolog miR-222 are clustered at Xp11.3 and are expressed from a single transcript. 21 Both miRNAs share an identical seed sequence 22 that has been reported to be upregulated in various tumors, including breast cancer. 23, 24 Both miRNAs were shown to promote cell growth, cell cycle progression and cell invasion in these cancer types in vitro and in vivo. 25, 26 Thus, they act as so-called 'oncomiRNAs'. Tissue inhibitor of metalloproteinase TIMP 3 is a common target of miR-221/222 in breast cancer cell lines and in primary human breast tumors. 27 The matrix metalloproteinases are a family of zinc proteases involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, tissue and bone remodeling, wound healing and angiogenesis. 28 Within the extracellular matrix, the tissue inhibitors of metalloproteinases, comprising four family members (TIMP [1] [2] [3] [4] , inhibit the activity of matrix metalloproteinases. 29 None is more intriguing than TIMP 3 , the only member of the family that shows a selective ability to inhibit several ADAMs (a disintegrin and metalloproteases) as well as matrix metalloproteinases. Previous studies have shown that overexpression of TIMP 3 in vascular smooth muscle cells and melanoma cell lines inhibits invasion and promotes apoptotic cell death.
New data suggest that high levels of TIMP 3 mRNA in human breast tumors are associated with success of adjuvant endocrine therapy. Delivery of TIMP 3 to tumor xenografts has confirmed its tumor suppressive activity in vivo. 30 High TIMP 3 levels result in stabilization of death receptors on the surface of breast cancer cells that enhances susceptibility to the apoptosis-inducing effects of tamoxifen. Furthermore, alteration in TIMP 3 level in breast cancer cells can modulate metalloprotease activity and mitogenic signaling, thereby contributing to tamoxifen sensitivity both in vitro and in vivo.
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Although aberrant expression of miRNAs in breast cancer has been widely reported, the functional consequences of altered expression of specific miRNAs in antiestrogen therapy-resistant breast cancer remain unclear. 32 There is considerable interest in elucidating the molecular mechanisms of acquired resistance to tamoxifen that might be exploited to stop the malignant progress of this disease. In theory, modulating miRNA expression by synthetic pre-miRNA molecules or antisense oligonucleotides may provide a powerful tool to study the biological and pathological functions of these regulatory molecules as well as the underlying molecular mechanisms. We sought to investigate the anticancer effects of miR-221 and miR-222 and their underlying molecular mechanisms in breast cancer by downregulating their expression in ER-positive and ER-negative breast cancer cell lines via antisense oligonucleotide transfection.
MATERIALS AND METHODS

Cell culture
ER-positive human breast cancer cell line MCF-7 (www.cellbank.org.cn) was cultured in RPMI-1640 medium (ATCC Modification) (Gibco, Grand Island, NY, USA). ER-negative human breast cancer cell line MDA-MB-231 (a gift from Dr Haihua Gu, Wenzhou Medical College School of Laboratory Medicine and Life Sciences, Wenzhou, Zhejiang, China) was cultured in high-glucose Dulbecco's modified Eagle's medium (with pyruvate; Gibco). All media were supplemented with 10% fetal calf serum (Euroclone, Milan, Italy) and 100 U ml À 1 penicillin-streptomycin. Cells were cultured at 37 1C in a 5% CO 2 atmosphere. 33 
Transfections
When cells in culture had grown to 80% confluence, the tissue culture medium was replaced with medium containing 1.6 mM (24 wells) or 3 mM (6 wells) of the plasmid per well. Breast cancer cells were transfected with plasmids containing the gene encoding green fluorescent protein (GFP) and antisense-miR-221 (AS-miR-221), antisense-miR-222 (AS-miR-222) or both (AS-miR-221/222) (GenePharma, Shanghai, China) to deplete the expression of miR-221 or/and miR-222. A nonrelevant miRNA sequence (miR-Scramble) was used as the negative control. For all transfections, Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) was used according to the manufacturer's instructions. 34 After transfection for 24 h, cells were examined under a fluorescence microscope for green fluorescence to determine transfection efficiency. Transfected cells from wells in which transfection efficiency was Z50% were grown in culture medium containing 800 mg ml À 1 G418 for 14 days to build stable cell lines. We verified the clones using western blot and real-time PCR, and pooled the successful clones for the experiments. In addition, all the experiments were also confirmed by transient transfection. The monoclonal breast cancer cells stably transfected with these molecules were used for further investigations. Total RNA and protein were extracted and stored at À 80 1C for subsequent real-time quantitative PCR or western blotting analysis.
RNA extraction
Total RNA, including miRNAs, was extracted from breast cancer cell lines with TRIzol (Invitrogen) according to the manufacturer's instructions and as previously described. 35 Total RNA was subjected to reverse transcription and the complementary DNA products stored at À 80 1C. The RNA was quantified by using a NanoDrop reader (Thermo Scientific, Waltham, MA, USA). Briefly, RNA (500 ng) in a 10 ml reaction mixture was reversetranscribed using the SYBR Perfect Ex Taq II (Perfect Real Time; Applied Takara Biosystems, Shiga, Japan) and subjected to real-time PCR using gene-specific, intron-spanning primers that had been designed with software that accompanies the SYBR Perfect Ex Taq II. The reactions were incubated first at 42 1C for 30 min, followed by inactivation at 85 1C for 5 min and then at 4 1C for 30 min.
Quantification of miRNAs and mRNA using quantitative real-time PCR Quantification of miR-221 and miR-222 in the G418-selected clones was performed by using SYBR Premix Ex Taq II (Perfect Real Time) assays (Applied TaKaRa Biosystems), followed by detection with the CFX96TM PCR detection system (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions (Technote 5859). The real-time quantitative PCR reaction conditions were as follows: denaturation at 95 1C for 5 min, followed by 40 cycles of denaturation at 95 1C for 10 s and annealing and extension at 60 1C for 30 s. 36 The U6 small nuclear RNA (Guanzhou Ribobio, Guanzhou, China) was used to normalize the relative abundance of miR-221 and miR-222. Data shown represent three independent experiments performed in triplicate.
For quantification of TIMP 3 , the appropriate primers were purchased from Sangon Biotech (Shanghai, China) and glyceraldehyde phosphate dehydrogenase (GAPDH) was used as a reference (housekeeping) 
Western blotting analysis
Once the transfected cell lines were established and stabilized, the cells were washed twice with ice-cold phosphate-buffered saline solution and reconstituted in ice-cold RIPA buffer containing 1 mmol l À 1 phenylmethanesulfonyl fluoride and a cocktail of protease inhibitors (1:100 dilution; Beyotime, Shanghai, China). Samples were subjected to centrifugation at 4 1C for 15 min at 14, 000 r.p.m. Supernatants were recovered, and total proteins were quantified by using the bicinchoninic acid assay (Beyotime). 35 Then, an aliquot of total protein (50 mg) treated with sodium dodecyl sulfate was subjected to electrophoresis on a 10% polyacrylamide gel. The proteins were then transferred onto an Immobilon-NC membrane (Millipore, Billerica, MA, USA). After blocking with Tris-buffered saline/ 0.05% Tween-20 (TBST) and 5% nonfat milk, the membrane was incubated with rabbit polyclonal anti-TIMP 3 antibody (1:1000 dilution; Bioworld Technology, Minneapolis, MN, USA) at 4 1C overnight. Membranes were washed with TBST and incubated with a secondary goat anti-rabbit IgG-HRP antibody (1:5000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted in TBST, for 1 h at room temperature. Finally, membranes were washed with TBST and developed using the ECL-detection system (Beyotime). Actin was used to confirm equal protein loading. The signals were detected and quantified by densitometry using Image Lab Software (Bio-Rad Laboratories).
Cell viability assay
The therapeutic effects of tamoxifen on miR-221-and/or miR-222-depleted breast cancer cells were determined. Both MCF-7 and MDA-MB-231cells (5000/well) were seeded in 96-well plates and treated with various concentrations of tamoxifen (0, 5, 10, and 20 mmol l À 1 ) for 12, 24 or 48 h after overnight serum starvation. Cell viability was measured using a Cell Counting Kit (CCK-8; Dojindo, Kumamoto, Japan) that is based on the bioreduction of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H tetrazolium sodium (WST-8) to orange-colored formazan. This method is widely used for the detection of cell viability and proliferation. In brief, 10 ml of CCK-8 assay reagent was added to each well at the indicated time and incubated at 37 1C for 2 h, followed by the addition of 100 ml solubilization reagent in each well. The absorbance was measured at 450 nm using an ELISA reader (Thermo Scientific).
Statistical analysis
Statistical analysis was performed using the SPSS17.0 software (Chicago, IL, USA). Each experiment was performed in triplicate and repeated at least three times, and all results are expressed as the mean±s.d. of results from Sensitivity of breast cancer cells to tamoxifen R Gan et al these independent experiments. Significance of differences between groups was determined by using the analysis of variance or unpaired two-tailed Student's t-test. A P-value of o0.05 was considered statistically significant. AS-miR transfection upregulates TIMP 3 mRNA expression in breast cancer cells As shown in Figure 3a , the levels of TIMP 3 mRNA were significantly increased following transfection with AS-miR-221 (3.6-fold versus Scramble; Po0.05), AS-miR-222 (2.6-fold versus Scramble; Po0.05) or AS-miR-221/222 (6.5 fold versus Scramble; Po0.01) in MCF-7 cells. Figure 3b shows similar, but less pronounced, effects on TIMP 3 (Figures 5a and b; P40.05). Other breast cancer cell lines were also tested and showed no difference (Supplementary Figure S1) . However, tamoxifen did significantly decrease viability of ER-positive MCF-7 cells transfected with AS-miR-221, AS-miR-222 or AS-miR-221/222. This effect became much more dramatic after prolonged incubation with tamoxifen (for 24 or 48 h) as compared with the Scramble group (Po0.05 to 0.01; Figure 6a ). Similar findings were also observed in other ER-positive breast cancer cell lines BT474 and T47D (Supplementary Figure S2) . In contrast, tamoxifen at various concentrations and time points had no inhibitory effect on viability of ER-negative MDA-MB-231 cells (P40.05; Figure 6b ). Tamoxifen is the current standard adjuvant therapy for ERpositive breast cancer. 37 Blocking the steroid hormone pathway with tamoxifen and/or oophorectomy has been shown to be effective in patients with this breast cancer subtype. Although endocrine therapy that blocks the ER pathway is a very effective treatment for ER-positive breast cancers, the response has not been uniform because of de novo or acquired resistance to this therapy. Although altered expression of miRNAs in ER-positive breast cancers has been used for tumor diagnosis and prognosis, the potential involvement of miRNAs in induction of drug resistance, particularly tamoxifen resistance, has not been fully explored. Recent studies showed significantly increased expression of eight miRNAs and downregulation of seven miRNAs in a tamoxifen-resistant breast cancer cell line compared with a tamoxifen-sensitive cell line. 18 In the present study, the viability of MCF-7 cells in which miR-221 and/or miR-222 was significantly downregulated by transfection with antisense miR oligonucleotides was reduced significantly by tamoxifen, suggesting that downregulation of miR-221/222 enhances the therapeutic sensitivity of MCF-7 cells to tamoxifen. Similar findings were also observed in ER-positive breast cancer cell lines BT474 and T47D. MiR-221/222 levels are known to be substantially higher in ERpositive breast cancers than in ER-negative breast cancers, and overexpression of these miRNAs causes MCF-7 cells to become tamoxifen resistant. 38 Miller et al. 20 showed that expression of miR-221 and miR-222 was significantly elevated in tamoxifenresistant breast cancer.
RESULTS
AS-miR-221, AS-miR-222 and AS-miR-
DISCUSSION
Although the success of adjuvant endocrine therapy is closely correlated with high levels of TIMP 3 mRNA, 39, 40 the underlying mechanisms of this association have not been studied in detail. Studies using the luciferase reporter assay and expression analysis have shown that TIMP 3 is a common target of miR-221/222. 41, 42 In the present study, we found that TIMP 3 expression was significantly increased following inhibition of miR-221/222. This increased expression of TIMP 3 was associated with decreased viability of ER-positive MCF-7 cells treated with tamoxifen. TIMP 3 is known to modulate metalloprotease activity and mitogenic signaling and thus may contribute to increased tamoxifen sensitivity of breast cancers both in vitro and in vivo. Our findings suggest that sensitivity to tamoxifen in resistant breast cancers could be increased by suppression of miR-221/222 expression and that this effect may be modulated by increased expression of TIMP 3 .
Studies are needed to demonstrate the direct link between miR-221/222 and TIMP3 by overexpressing the two microRNAs or TIMP 3 in cells to investigate the functional effects. More importantly, further investigation of the in vivo effect of miR-221/222 using an animal model is warranted.
Increasing interest is focusing on identifying novel therapeutic approaches that downregulate the expression of carcinogenic miRNAs. 43, 44 A recent study demonstrated that systemically delivered unconjugated tiny locked nucleic acid oligonucleotides could be taken up by mouse mammary tumors, leading to longterm miRNA silencing. 45 In another study, tumor growth was suppressed through in vivo administration of cholesterol-modified anti-miR-221 that suggests that miR-221 may be a viable therapeutic target for the treatment of aggressive cancers. 46 Similar studies in gemcitabine-resistant cholangiocarcinoma showed that inhibition of miR-21 and miR-200b sensitized cholangiocytes to gemcitabine. 47 Finally, Lu et al. 5 showed that expression of miR-221 and miR-222 was increased in tamoxifen-resistant MCF-7 cells. They also observed increased tamoxifen sensitivity of tamoxifenresistant xenografts in mice treated with a combination of tamoxifen and anti-miR-221/222. They further demonstrated that increased expression of TIMP 3 inhibited cell growth whereas depletion of TIMP 3 reduced MCF-7 cell sensitivity to tamoxifen, suggesting that downregulating miRs and upregulating TIMP 3 could be a viable therapeutic approach to enhancing tumor response to tamoxifen. 5 In summary, we established a cell culture model in which miR-221 and miR-222 expression was downregulated by using antisense oligonucleotide transfection in MCF-7 and MDA-MB-231 breast cancer cell lines. Inhibition of miR-221/222 expression in these cells upregulated TIMP 3 expression, enhanced breast cancer cell sensitivity to tamoxifen and significantly suppressed cell proliferation. These latter effects may be modulated by the upregulation of TIMP 3 . Thus, upregulation of TIMP 3 by anti-miR-221/222 therapy may increase the tamoxifen sensitivity of ERpositive breast cancer cells. Our findings may provide a promising therapeutic approach for treating hormone-independent and tamoxifen-resistant breast cancer.
